Anteris Technologies Global Corp. (AVR)
NASDAQ:AVR
Want to see AVR full AI Analyst Report?
AVR Stock Chart & Stats
$5.68
-$0.12(-2.09%)
At close: 4:00 PM EST
$5.68
-$0.12(-2.09%)
Day’s Range― - ―
52-Week Range$2.85 - $10.14
Previous Close$5.88
Volume157.53K
Average Volume (3M)151.40K
Market Cap
$906.26M
Enterprise Value$37.64M
Total Cash (Recent Filing)$283.21M
Total Debt (Recent Filing)$3.73M
Price to Earnings (P/E)―
Beta1.81
Next Earnings
Aug 17, 2026EPS Estimate
-0.21Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.00
Shares Outstanding97,342,200
10 Day Avg. Volume215,658
30 Day Avg. Volume151,395
Financial Highlights & Ratios
PEG Ratio-0.20
Price to Book (P/B)-1.27K
Price to Sales (P/S)61.50
P/FCF Ratio-1.48
Enterprise Value/Market Cap0.04
Enterprise Value/Revenue20.34
Enterprise Value/Gross Profit71.97
Enterprise Value/Ebitda-0.41
Forecast
1Y Price Target
$16.00Price Target Upside181.69% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-1.17
Revenue Forecast (FY)$7.88M
Bulls Say, Bears Say
Bulls Say
Low Leverage / Balance Sheet FlexibilityReported minimal debt and very low debt-to-equity provide durable solvency flexibility, reducing near-term bankruptcy risk and preserving capacity to raise or deploy capital. Over 2–6 months this supports strategic options (funding, partnerships, manufacturing scale) despite uneven historical balance-sheet volatility.
Strengthened Governance And Financial LeadershipAdding an experienced finance executive and reinforcing audit oversight materially improves board-level financial governance and risk management. Durable improvement in oversight increases credibility with investors and lenders and enhances long-term capital allocation, compliance and strategic execution.
Operational Build-out With Large New FacilityA long-term 181k sq ft lease signals intentional capacity expansion to support manufacturing and commercialization of DurAVR. The facility and initial rent abatements give runway to scale production and supply chain setup, strengthening structural ability to commercialize products if clinical/commercial traction follows.
Bears Say
Severe And Persistent Cash BurnSustained, large negative operating and free cash flows create a structural financing and runway risk. Over the next several months the company cannot self-fund operations at current burn rates, forcing financing choices that can constrain strategy or require dilution if operating losses persist.
Declining, Very Small Revenue BaseRevenue is minimal and has been shrinking, leaving a large mismatch versus operating costs. This weak commercial traction undermines margin sustainability and suggests the business is not yet generating durable product-market fit or enough sales to support scaling without continued external funding.
Reliance On Equity Financing / Dilution RiskA $250M at-the-market program provides flexible capital but signals dependency on equity markets to fund development. Over 2–6 months this raises dilution risk and highlights lack of self-sustaining cash generation, potentially weakening existing shareholders and limiting capital structure optionality.
Anteris Technologies Global Corp. News
AVR FAQ
What was Anteris Technologies Global Corp.’s price range in the past 12 months?
Anteris Technologies Global Corp. lowest stock price was $2.85 and its highest was $10.14 in the past 12 months.
What is Anteris Technologies Global Corp.’s market cap?
Anteris Technologies Global Corp.’s market cap is $906.26M.
When is Anteris Technologies Global Corp.’s upcoming earnings report date?
Anteris Technologies Global Corp.’s upcoming earnings report date is Aug 17, 2026 which is in 65 days.
How were Anteris Technologies Global Corp.’s earnings last quarter?
Anteris Technologies Global Corp. released its earnings results on May 12, 2026. The company reported -$0.28 earnings per share for the quarter, missing the consensus estimate of -$0.271 by -$0.009.
Is Anteris Technologies Global Corp. overvalued?
According to Wall Street analysts Anteris Technologies Global Corp.’s price is currently Undervalued.
Does Anteris Technologies Global Corp. pay dividends?
Anteris Technologies Global Corp. does not currently pay dividends.
What is Anteris Technologies Global Corp.’s EPS estimate?
Anteris Technologies Global Corp.’s EPS estimate is -0.21.
How many shares outstanding does Anteris Technologies Global Corp. have?
Anteris Technologies Global Corp. has 97,342,200 shares outstanding.
What happened to Anteris Technologies Global Corp.’s price movement after its last earnings report?
Anteris Technologies Global Corp. reported an EPS of -$0.28 in its last earnings report, missing expectations of -$0.271. Following the earnings report the stock price went down -2.537%.
Which hedge fund is a major shareholder of Anteris Technologies Global Corp.?
Currently, no hedge funds are holding shares in AVR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Anteris Technologies Global Corp. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$16.00 (181.69% Upside)
$16.00 (181.69% Upside)
Hedge Fund Trend
Increased
By 5.4M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $102.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 4.7%
Last 30 Days ▼ 0.3%
Last 30 Days ▼ 0.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-14.53%
12-Months-Change
Fundamentals
Return on Equity
-124.39%
Trailing 12-Months
Asset Growth
401.30%
Trailing 12-Months
Company Description
Anteris Technologies Global Corp.
Anteris Technologies Global Corp. is a structural heart innovator dedicated to discovering, developing, and bringing to market medical devices that enhance the well-being of patients grappling with aortic stenosis. The company's premier offering is the DurAVR transcatheter heart valve system, a pioneering transcatheter aortic valve engineered to treat aortic stenosis by precisely emulating the performance of a healthy human aortic valve. Beyond this, Anteris develops ADAPT anti-calcification tissue, a unique preparation that transforms xenograft tissue into robust bioscaffolds. These bioscaffolds are designed to simulate human tissue for various surgical repairs, notably in aortic valve replacement. Additionally, the ComASUR delivery system, a physician-designed balloon-expandable apparatus, features a reinforced, steerable catheter. This allows for highly accurate navigation through cardiac anatomy in a controlled manner, thereby mitigating potential damage to the aorta. Founded in 1999, Anteris Technologies Global Corp. operates out of Toowong, Australia.
AVR Stock 12 Month Forecast
Average Price Target
$16.00
▲(181.69% Upside)
Technical Analysis
Anika Therapeutics
―
Apyx Medical
―
Inogen
―
Treace Medical Concepts
―
Rapid Micro Biosystems
―
Ownership Overview
14.07% Insiders
5.14% Mutual Funds
44.76% Other Institutional Investors
31.46% Public Companies and
Individual Investors